The Efficacy and Biopharmaceutical Properties of a Fixed-Dose Combination of Disulfiram and Benzyl Benzoate

dc.contributor.authorLajarin Reinares, Maria
dc.contributor.authorMartínez-Esteve, Elia
dc.contributor.authorPena-Rodríguez, Eloy
dc.contributor.authorCañellas-Santos, Mariona
dc.contributor.authorBulut, Sanja
dc.contributor.authorKarabelas, Kostas
dc.contributor.authorClauss, Adam
dc.contributor.authorNieto Abad, Carlos
dc.contributor.authorMallandrich Miret, Mireia
dc.contributor.authorFernández Campos, Francisco
dc.date.accessioned2022-12-15T10:59:37Z
dc.date.available2022-12-15T10:59:37Z
dc.date.issued2022-09
dc.date.updated2022-12-15T10:59:37Z
dc.description.abstractScabies and hair lice are parasitic diseases that affect human skin and hair, respectively. The incidence and resistances of these infections are increasing. Tenutex® (disulfiram and benzyl benzoate emulsion) is an alternative to standard insecticides to avoid resistances. The aim of the work is to evaluate the transdermal absorption and the in vitro efficacy against scabies and hair lice after different exposition times. Dermatomed human skin was used to assess the dermal absorption using a validated High Performance Liquid Chromatography (HPLC) method. HEK001 keratinocytes were used to evaluate the cytotoxicity of benzyl benzoate. Only benzyl benzoate was able to cross the skin, but it did not show cytotoxicity at any of the tested concentrations. The product efficacy was tested on Psoroptes ovis after direct contact and after administration on sheep skin explants at different contact times. Permethrin/malathion-resistant strains of Pediculus humanis capitis adults and eggs were directly exposed to Tenutex, and the vitality and hatchability, respectively, were evaluated. The anti-scabies study demonstrated that exposure for 6 or 24 h completely eradicated the parasite. The pediculicidal activity of Tenutex exhibited superior efficacy than standard treatment on resistant lice. The positive results obtained suggest that Tenutex® is a good treatment option, especially in drug resistance situations.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec725147
dc.identifier.issn1999-4923
dc.identifier.urihttps://hdl.handle.net/2445/191604
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms231810969
dc.relation.ispartofPharmaceutics, 2022, vol. 23, num. 18
dc.relation.urihttps://doi.org/10.3390/ijms231810969
dc.rightscc-by (c) Lajarin Reinares, Maria et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationInfeccions
dc.subject.classificationRonya
dc.subject.classificationMedicació transdèrmica
dc.subject.otherInfections
dc.subject.otherScabies
dc.subject.otherTransdermal medication
dc.titleThe Efficacy and Biopharmaceutical Properties of a Fixed-Dose Combination of Disulfiram and Benzyl Benzoate
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
725147.pdf
Mida:
1.63 MB
Format:
Adobe Portable Document Format